Merck & Co., Inc: Hematologic Neoplasms trials
The registry lists 11 Hematologic Neoplasms studies with Merck & Co., Inc as lead sponsor. 3 are open to participants now and 3 have results posted.
Phase 1 4Phase 2 5Phase 3 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)RecruitingNCT07709000Phase 2
- Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)RecruitingNCT04728893Phase 2
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingNCT03486873Phase 3
- A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)CompletedNCT05005442Phase 2Results posted
- A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)CompletedNCT01254630Phase 3Results posted
- Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)CompletedNCT01254318Results posted
- A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)CompletedNCT06586671Phase 1
- A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)Active, not recruitingNCT05347225Phase 1
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic MalignanciesCompletedNCT00825487Phase 1
- Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)CompletedNCT00086125Phase 2